The Rotation To Value Is On – 5 October Surprise High-Yield Picks

An 'October Surprise' is signaling a significant rotation of fund flows from large-cap growth stocks to value stocks, despite major indices trading at all-time highs. This shift is presented as a strategic opportunity for investors seeking high-yield value dividend stocks, particularly in anticipation of Federal Reserve interest rate cuts, with historical data supporting dividend payers' outperformance. The article identifies five specific large-cap value dividend stocks—Exxon Mobil, Medtronic, Merck, PepsiCo, and U.S. Bancorp—each trading below fair value with attractive dividend yields and Wall Street 'Buy' ratings.

Analysis

Investing The Rotation To Value Is On – 5 October Surprise High-Yield Picks By Lee Jackson Oct 5, 2025 | Updated 11:56 AM ET This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. An “October Surprise” is usually a significant, late-breaking news event that generally occurs just before a November election and has the potential to influence its outcome. These events can be intentional, such as a planned political attack, or unexpected, like a major news story that emerges spontaneously. While there is no election this year, the big financial “October Surprise” is that fund flows are starting to indicate a rotation from large-cap growth stocks to value. While the inclination of many to continue investing in technology stocks, especially those with an AI component, remains in place, weekly all-time highs in all the major indices are starting to move flows to value. 24/7 Wall St. Key Points: - Large cap value dividend stocks are starting to see more and more investor rotation. - With the market trading at all-time highs, it makes sense to move to value stocks with high yields. - High-yield value dividend stocks are likely to perform well as the Federal Reserve lowers interest rates. - Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; learn more here.(Sponsor) A value stock is generally a company that trades at a price lower than its fundamental value or what its performance suggests it should be worth. Typically, these are shares of a company with solid fundamentals that are priced below those of its peers, based on an analysis of the price-to-earnings ratio, yield, price-to-book value, and other relevant factors. Value stocks are often overlooked by the market or undervalued due to factors such as market volatility, economic downturns, or negative news surrounding the company, which may be temporary in nature. We screened our 24/7 Wall St. large-cap value research database, looking for companies that pay reliable and significant dividends. Five of our favorite stocks have appeared on our screens, and all are rated Buy by top Wall Street firms, offering safety and strong upside potential. Why do we cover Value dividend stocks? Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciation has contributed 68%. Therefore, sustainable dividend income and capital appreciation potential are essential for total return expectations. A study by Hartford Funds, in collaboration with Ned Davis Research, found that dividend stocks delivered an annualized return of 9.18% over the 50 years from 1973 to 2023. Over the same timeline, this was more than double the annualized return for non-payers (3.95%). Exxon Mobil ExxonMobil manages an industry-leading portfolio of resources and is one of the world’s largest integrated energy companies, with operations spanning fuels, lubricants, and chemicals. The decline in oil prices presents investors with an excellent entry point, as the shares are trading 14% below fair value with a 3.34% dividend yield. Exxon Mobil Corporation (NYSE: XOM) is the world’s largest international integrated oil and gas company, exploring for and producing crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. Exxon Mobil also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene, and polypropylene plastics, as well as specialty products. Additionally, the company transports and sells crude oil, natural gas, and petroleum products. Top Wall Street analysts expect the company to remain a key beneficiary in a higher oil price environment, and most remain very optimistic about the company’s sharp positive inflection in capital allocation strategy. Upstream portfolio and leverage to a further demand recovery. ExxonMobil offers greater Downstream/Chemicals exposure than its peers. Exxon Mobil has completed its purchase of oil shale giant Pioneer Natural Resources Company in an all-stock transaction valued at $59.5 billion. The deal created the largest U.S. oil field producer and guarantees a decade of low-cost production. Medtronic Medtronic plc (NYSE: MDT) is a medical technology giant trading 20% below its fair value with a 2.94% yield. It has been returning 60-70% of free cash flow to shareholders, making it the perfect stock for those seeking a safe position in the healthcare devices sector. The company develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers: - Implantable cardiac pacemakers - Cardioverter defibrillators - Cardiac resynchronization therapy devices - Cardiac ablation products - Insertable cardiac monitor systems - TYRX products, remote monitoring, and patient-centered software It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, transcatheter pulmonary valves, percutaneous coronary intervention products, and percutaneous angioplasty balloons. The Neuroscience Portfolio segment offers: - Medical devices and implants - Biologic solutions - Spinal cord stimulation and brain modulation systems - Implantable drug infusion systems - Interventional products - Nerve ablation systems under the Accurian name The segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, interventional radiologists, ear, nose, and throat specialists, as well as energy surgical instruments. The Medical Surgical Portfolio segment offers: - Surgical stapling devices - Vessel sealing instruments - Wound closure and electrosurgery products - AI-powered surgical video and analytics platform - Robotic-assisted surgery products - Hernia mechanical devices - Mesh implants - Gynecology products - Gastrointestinal and hepatologic diagnostics and therapies - Therapies to treat other non-exclusive diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, an innovative insulin pen system. Merck Merck develops and produces medicines, vaccines, biological therapies, and animal health products. Merck & Co. Inc. (NYSE: MRK) is not just a healthcare company but a global force in the industry. This healthcare giant is trading 25% below fair value with a 3.53% yield, making it one of the more undervalued options. The company operates through two segments: - Pharmaceutical - Animal Health The Pharmaceutical segment offers human health pharmaceutical products in: - Oncology - Hospital acute care - Immunology - Neuroscience - Virology - Cardiovascular - Diabetes - Vaccine products, such as preventive pediatric, adolescent, and adult vaccines The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. Merck serves: - Drug wholesalers - Retailers - Hospitals - Government agencies - Managed healthcare providers, such as health maintenance organizations - Pharmacy benefit managers and other institutions - Physicians - Physician distributors - Veterinarians - Animal producers Merck’s growth is a result of its efforts and strategic collaborations. The company works with AstraZeneca PLC (NYSE: AZN), Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. (NASDAQ: GILD) to jointly develop and commercialize long-acting treatments for HIV, demonstrating a commitment to innovation and growth. PepsiCo This top consumer staples stock posted solid earnings for the second quarter and will supply all the goods for the NFL football season, tailgates, and parties. Trading 17% below fair value with a 3.83% yield, the stock is also a dividend aristocrat. PepsiCo, Inc. (NYSE: PEP) is a worldwide food and beverage company. Its Frito-Lay North America segment offers - Lays and Ruffles potato chips - Doritos, Tostitos, and Santitas tortilla chips - Cheetos cheese-flavored snacks, branded dips - Fritos corn chips The company’s Quaker Foods North America segment provides: - Quaker Oatmeal - Grits - Rice cakes - Natural granola and oat squares - Pearl Milling mixes and syrups - Quaker Chewy granola bars - Cap’n Crunch cereal - Life cereal - Rice-A-Roni side dishes Pepsico’s North America Beverages segment offers beverage concentrates, fountain syrups, and finished goods under these brands: - Pepsi - Gatorade - Mountain Dew - Diet Pepsi - Aquafina - Diet Mountain Dew - Tropicana Pure Premium - Sierra Mist - Mug brands U.S. Bancorp Based in Minneapolis, this Super-Regional financial giant is an outstanding choice for growth and income investors now. U.S. Bancorp (NYSE: USB) is a financial services holding company that is trading 11% below fair value, with the highest yield on this list at 4.17% The bank’s segments are: - Wealth - Corporate - Commercial and Institutional Banking - Consumer and Business Banking - Payment Services - Treasury and Corporate Support It offers a comprehensive range of financial services, including lending and deposit services, cash management, capital markets, and trust and investment management services. It also engages in credit card services, merchant and ATM processing, mortgage banking, insurance, brokerage, and leasing. The company’s banking subsidiary, U.S. Bank National Association (USBNA), is engaged in the banking business, principally in domestic markets. USBNA provides a range of products and services to individuals, businesses, institutional organizations, governmental entities, and other financial institutions. I The non-banking subsidiaries offer investment and insurance products to customers primarily within their domestic markets, as well as fund administration services to a range of mutual and other funds. Oppenheimer has assigned an Outperform rating with a target price of $67. Get Ready To Retire (Sponsored) Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. Here’s how it works: 1. Answer SmartAsset advisor match quiz 2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles. 3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future.The image featured for this article is © 24/7 Wall St. Latest Podcast Episode AI Companies Entering A Game of Chips More Wild Than Westeros 62 min A significant rotation in fund flows from large-cap growth stocks into value equities is reportedly occurring, despite major indices trading at all-time highs. This market dynamic is presented as a strategic move by investors to capture value in companies with solid fundamentals trading below their intrinsic worth. The bullish thesis for this rotation is heavily supported by the anticipation of future Federal Reserve interest rate cuts, which are expected to enhance the attractiveness of high-yield dividend stocks. The argument is buttressed by historical data indicating dividend-paying stocks delivered an annualized return of 9.18% over the 50 years to 2023, significantly outperforming non-payers. Five specific large-cap companies are highlighted as beneficiaries of this trend: Exxon Mobil (XOM), Medtronic (MDT), Merck (MRK), PepsiCo (PEP), and U.S. Bancorp (USB). Each is identified as trading at a notable discount to fair value, ranging from 11% (USB) to 25% (MRK), while offering dividend yields between 2.94% and 4.17%. The analysis points to specific strengths, such as Exxon's recent $59.5 billion acquisition of Pioneer Natural Resources, Medtronic's policy of returning 60-70% of free cash flow to shareholders, and U.S. Bancorp's 'Outperform' rating from Oppenheimer.

Key Decisions for Investors

• Investors with significant exposure to large-cap growth should consider a partial rebalancing towards high-yield value equities to align with the observed fund flow rotation and mitigate concentration risk from markets trading at all-time highs.
• The investment thesis is highly contingent on future Federal Reserve rate cuts, making it critical to monitor central bank communications and macroeconomic indicators that would support a more dovish monetary policy.
• The five featured stocks—XOM, MDT, MRK, PEP, and USB—warrant further due diligence as they are presented as undervalued with strong dividend support; investors should evaluate their individual sector outlooks and fundamental catalysts.
• Given the high dividend yields, particularly U.S. Bancorp's 4.17%, income-focused investors may find these names attractive, but should verify the sustainability of the payouts through balance sheet and cash flow analysis.